1-Adamantaneethanol

1-Adamantaneethanol is an allele-selective MHC II class molecule loading enhancer (MHC loading enhancer, MLE) that enhances peptide loading and ligand exchange of HLA-DR molecules. 1-Adamantaneethanol targets the polymorphic P1 pocket of HLA-DR molecules and preferentially acts on HLA-DR subtypes with Gly at position β86, thereby stabilizing the peptide-receptor conformation and accelerating antigen loading. 1-Adamantaneethanol can be used in studies related to MHC II antigen presentation, peptide vaccines, adaptive immunity and tumor immunity^[1][2].
In Vitro:1-Adamantaneethanol (1 mM; soluble DRB10101) promotes MHC II ligand exchange, causing preloaded IC106-120 to dissociate from DRB10101 within <6 h in the presence of high-affinity HA306-318, whereas almost no exchange occurs without the catalyst^[1].
1-Adamantaneethanol (62.5-1000 μM; soluble DRB10101) accelerates HA306-318 peptide loading in a concentration-dependent manner; at 1 mM, it reduces the time required to reach half-maximal peptide loading from >20 h without a catalyst to approximately 30 min, and the enhancement of peptide loading rate remains unsaturated even at the highest concentration of 1 mM^[1].
1-Adamantaneethanol (4 h) selectively enhances cell surface peptide loading of HLA-DR subtypes with Gly86, including DRB10101, DRB10401, DRB11502, DRB11602 and DRB50101, whereas Val86-containing DRB11501 is insensitive to AdEtOH; the Gly86→Val mutation abolishes the response, while the Val86→Gly mutation confers responsiveness to DRB11501^[1].
1-Adamantaneethanol (50-250 μM; 4 h; DRB10101-expressing 721.221 cells) enhances HA306-318-specific CD4⁺ T cell responses in a concentration-dependent manner^[1].
1-Adamantaneethanol (250 μM; 4 h) enhances CD4⁺ T-cell responses mediated by DRB10101-, DRB10401- and DRB11502-restricted antigen presentation, but does not enhance DRB11501-restricted responses, further indicating that its immunopotentiating effect is HLA-DR allele-selective^[1].
1-Adamantaneethanol (250 μM; 4 h; bone marrow-derived dendritic cells from HLA-DR4 transgenic mice) enhances cell surface loading of HA306-318, increasing the streptavidin fluorescence MFI from 430 in the peptide alone group to 1607, and augments HLA-DR1/DR4-restricted HA306-318-specific CD4⁺ T cell responses^[2].
1-Adamantaneethanol (250 μM; 4 h; HLA-DR-transfected L929 cells) enhances cell surface loading of the tumor-associated antigen NY-ESO-1 epitopes, with a significant enhancement in the loading of NY-ESO-1 89-101 onto HLA-DR1 and a weaker enhancement in the loading of NY-ESO-1 119-143 onto HLA-DR4^[2]. In Vivo:After subcutaneous immunization with the combination of 1-Adamantaneethanol (2 μmol/mouse; s.c.; HLA-DR1 transgenic mice), HA306-318 antigen, IFA and CpG, the proportion of HA-specific CD4⁺CD154⁺IFN-γ⁺ T cells increases from 0.104% to 0.432% on day 12, representing an over 4-fold increase^[2].
Co-immunization with 1-Adamantaneethanol (2 μmol/mouse; s.c.; HLA-DR1 transgenic mice), HA306-318, IFA and CpG significantly increases the number of HA-specific IFN-γ-secreting T cells, while no significant enhancement is observed in BALB/c mice, indicating that its in vivo immunopotentiating effect is HLA-DR selective^[2].
Combined immunization of HLA-DR1 transgenic mice with 1-Adamantaneethanol (2 μmol/mouse; s.c.) and 5 μg NY-ESO-1 89-101 increases the proportion of mice responding to this tumor-associated antigen from 4/13 to 12/13, and significantly elevates the number of IFN-γ-secreting cells^[2].
Co-immunization with 1-Adamantaneethanol (2 μmol/mouse; s.c.; HLA-DR1 transgenic mice) and 10 μg recombinant NY-ESO-1 protein increases the proportion of NY-ESO-1-specific CD4⁺CD154⁺IFN-γ⁺ T cells from 0.064% to 0.23% on day 12, and elevates the sensitivity of NY-ESO-1-specific immune responses by nearly one order of magnitude^[2].